Alimera Sciences is a pharmaceutical company that is engaged in the commercialization and development of prescription ophthalmic pharmaceuticals. The company's commercial product is ILUVIEN?, an intravitreal implant that treats patients by delivering a continuous microdose of the non-proprietary corticosteroid fluocinolone acetonide in the eye. ILUVIEN was initially developed to treat diabetic macular edema, a disease of the retina that affects individuals with diabetes and can lead to vision loss and blindness. The company commercially markets ILUVIEN in the United States, Germany, the United Kingdom, Portugal, Austria and Ireland. The company has three segments: the United States, International and Other.

Aptinyx is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of synthetic small molecules for the treatment of brain and nervous system disorders. The company's product candidates comprised of: NYX 2925, which is a small molecule N-methyl-D-aspartate receptors (NMDAr) modulator being developed for the treatment of chronic pain; NYX-783, which is a small-molecule NMDAr modulator in development for the treatment of post-traumatic stress disorder; NYX-458, which is a small-molecule NMDAr modulator in development for the treatment of Parkinson's disease cognitive impairment; and AGN-241751, which is for the treatment of depressive disorder.

BioDelivery Sciences International is a pharmaceutical company with a focus on patients living with chronic pain and associated conditions. The company has built a portfolio of products that includes utilizing its proprietary BioErodible MucoAdhesive drug-delivery technology to develop and commercialize new applications of proven therapies aimed at addressing unmet medical needs. The company's product candidates include: BELBUCA for the management of pain severe enough to require long-term opioid treatment and for which alternative treatment options are inadequate; and Symproic for the management of opioid-induced constipation in adult patients with chronic non-cancer pain.

Charles & Colvard manufactures, markets, and distributes Charles & Colvard Created Moissanite? (which the company refers to as moissanite or moissanite jewels) and finished jewelry featuring its proprietary moissanite gemstone for sale in the worldwide jewelry market. The company sells loose moissanite jewels and finished jewelry through various operating segments: its Online Channels segment, which comprises its charlesandcolvard.com website, e-commerce outlets, including marketplaces, drop-ship customers, and other e-commerce customers; and its Traditional segment, which consists of domestic and international distributors and retail customers.

Chegg provides products and services that help students improve their outcomes throughout their educational journey. The company's offerings fall into two categories: Chegg Services, which encompasses all of its digital products and services such as Chegg Study, Chegg Writing, Chegg Tutors, Chegg Math Solver, and Other Services; and Required Materials, which primarily includes its print textbook and eTextbook offering. To deliver services to students, the company partners with a variety of third parties. The company sources print textbooks, eTextbooks, and supplemental materials directly or indirectly from publishers including Cengage Learning, Pearson, McGraw Hill, Sage Publications, and MacMillan.

Kingsway Financial Services is a holding company. Through its subsidiaries, Co. operates as a merchant bank engaged in the property and casualty insurance business. Co. operates three segments: Insurance Underwriting, which markets automobile insurance products that provide coverage in three main areas: liability, accident benefits and physical damage; Insurance Services, which includes IWS Acquisition Corporation, a licensed motor vehicle service agreement company, and Trinity Warranty Solutions LLC, a provider of warranty products and maintenance support; and Leased Real Estate, which includes Co.'s subsidiary, CMC Industries, Inc., that owns a parcel of real property located in Texas.

Kirkland's is a retailer of home decor in the U.S., operating in stores as well as an e-commerce enabled website, www.kirklands.com. The company's stores present a selection of merchandise, including holiday decor, furniture, art, fragrance and accessories, ornamental wall decor, decorative accessories, mirrors, lamps, textiles, artificial floral products, gifts, housewares, outdoor living items, frames and clocks. The company's stores provides assortment of holiday merchandise during seasonal periods as well as items carried throughout the year suitable for gift-giving. The company provides its customers an engaging shopping experience characterized by merchandise selection reflecting existing styles.

CUI Global is a platform company engaged in the acquisition, development and commercialization of new technologies and businesses. The company's operations fall into these reportable segments: Power and Electromechanical segment, which provides electronic components including power supplies, transformers, converters, connectors and industrial controls for original equipment manufacturers through its subsidiaries; and Energy Segment, which has developed a portfolio of products, services and resources to provide a range of personalized gas engineering solutions to the gas utilities, power generation, emissions, manufacturing and automotive industries through its subsidiaries.

Organogenesis Holdings is a regenerative medicine company focused on the development, manufacture and commercialization of solutions. The company's Advanced Wound Care products include Apligraf for the treatment of VLUs and DFUs; Dermagraft for the treatment of DFUs; PuraPly Antimicrobial (PuraPly AM) to address biofilm across various wound types; and Affinity and NuShield to address various wound sizes and types. The company's Surgical and Sports Medicine products include ReNu for in-office joint and tendon applications; NuCel for bony fusion in the spine and extremities; NuShield and Affinity for surgical application in targeted soft tissue repairs; and PuraPly AM for surgical treatment of open wounds.

Proto Labs is a digital manufacturer of custom prototypes and production parts. The company's primary manufacturing product lines include Injection Molding, which uses three-dimensional (3D) computer-aided design-to-computer numerical control (CNC) machining technology for the automated design and manufacture of molds; CNC Machining, which uses commercially available CNC machines to provide milling and turning; 3D Printing, which includes stereolithography, selective laser sintering, direct metal laser sintering, Multi Jet Fusion and PolyJet processes; and Sheet Metal, which includes e-commerce-enabled custom sheet metal parts, providing customers with prototype and low-volume production parts.

Provention Bio is a clinical stage biopharmaceutical company focused on the development and commercialization of therapeutics and solutions to intercept and prevent immune-mediated diseases. The company's principal product candidates include: PRV-031 (teplizumab, anti-CD3 mAb) for the interception of type 1 diabetes; PRV-015 (anti-IL-15 mAb) for the treatment of gluten-free diet non-responding celiac disease; PRV-6527 (oral CSF-1R inhibitor) for the treatment of Crohn's disease; PRV-300 (anti-TLR3 mAb) for the treatment of ulcerative colitis; and PRV-3279 (humanized anti-CD32B and CD79B bispecific) for the treatment of lupus.

Revance Therapeutics is a clinical-stage biotechnology company focused on the development, manufacturing and commercialization of neuromodulators for multiple aesthetic and therapeutic indications. The company focuses on developing daxibotulinumtoxinA, its purified botulinum toxin Type A, for a spectrum of aesthetic and therapeutic indications, including facial wrinkles, muscle disorders, and chronic migraine. The company's main drug candidate is DaxibotulinumtoxinA for Injection. The company also is developing a topically applied neuromodulator for aesthetic and therapeutic indications, DaxibotulinumtoxinA Topical, and have a collaboration and license agreement to develop and commercialize a biosimilar to BOTOX?.

Safehold is a holding company. Through its subsidiaries, the company operates its business through one segment by acquiring, managing and capitalizing ground leases. Ground leases generally represent the ownership of land underlying commercial real estate properties, which are leased on a long-term basis (base terms are 30 to 99 years, often with tenant renewal options) by the land owner to a tenant that owns and operates the building on top of the land, or what the company refer to as a Safehold?.

Selecta Biosciences is a biopharmaceutical company using its ImmTOR? platform, designed to induce tolerance to biologic therapies that would otherwise be limited by immunogenicity to treat rare and serious diseases. The company's product candidate, SEL-212, is a combination of a therapeutic uricase enzyme (pegadricase) and its ImmTOR platform that is designed to control serum uric acid levels in patients with chronic refractory gout through monthly administration. The company is applying its ImmTOR platform to mitigate the formation of anti-drug antibodies when dosing gene therapy. The company's investigational gene therapy program targets the treatment of rare genetic diseases, including methylmalonic acidemia.

Six Flags Entertainment is a theme park operator and also an operator of waterparks. The company's parks provide a selection of thrill rides, water attractions, themed areas, concerts and shows, restaurants, game venues and retail outlets. The company holds licenses for theme park usage of certain Warner Bros. and DC Comics characters throughout the U.S. (except the Las Vegas metropolitan area), Canada, Mexico and other countries. The company's licenses include the right to sell merchandise featuring the characters at the parks, and to use the characters in its advertising, as walk-around characters and in theming for rides, attractions and retail outlets.

Verrica Pharmaceuticals is a dermatology therapeutics company focused on the development and commercialization of treatments for people living with skin diseases. The company's primary product candidate, VP-102, is a proprietary drug-device combination of its topical solution of cantharidin, a naturally sourced agent to treat topical dermatological conditions, administered through its single-use precision applicator. The company is initially developing VP-102 for the treatment of molluscum contagiosum, or molluscum, a highly contagious and primarily pediatric viral skin disease, and common warts. In addition, the company is also developing VP-102 for the treatment of external genital warts.